Search results for "ANTIBODIES"

showing 10 items of 1885 documents

Limited antibody specificity compromises epitranscriptomic analyses

2019

International audience; A controversial discussion on the occurrence of the RNA modification m1A in mRNA takes a new turn, as an antibody with a central role in modification mapping was shown to also bind mRNA cap structures.

0301 basic medicineScienceGeneral Physics and Astronomy02 engineering and technologyPlasma protein bindingAntibodiesGeneral Biochemistry Genetics and Molecular BiologyEpigenesis GeneticTranscriptome03 medical and health sciencesAntibody Specificity[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]AnimalsHumansRNA Messengerlcsh:ScienceEpigenesisRegulation of gene expressionMessenger RNAMultidisciplinarybiologyCommentQRNA[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyGeneral ChemistryDNA MethylationRNA modification021001 nanoscience & nanotechnologyCell biology030104 developmental biologyGene Expression RegulationDNA methylationbiology.proteinRNAlcsh:QAntibodyTranscriptome0210 nano-technologyProtein Binding
researchProduct

Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?

2018

Anti-PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent lipid-lowering drugs. They demonstrated to improve the lipid profile in high cardiovascular risk patients. Anti-PCSK9 Mab inhibit the targeted low-density lipoprotein (LDL)-receptor degradation induced by PCSK9 protein and are able to reduce LDL cholesterol (LDL-C) levels on top of conventional lipid-lowering therapy. Though these drugs proved to be very safe in the short-term, little is known about the possible long-term effects, due to the short period of their marketing. The genetic low cholesterol syndromes (LCS) represent the natural models of the lipid-lowering anti-PCSK9 therapy, and a…

0301 basic medicineSerine Proteinase InhibitorsTime FactorsPhysiologymedicine.drug_class030204 cardiovascular system & hematologyPharmacologyMonoclonal antibodyRisk Assessment03 medical and health sciencesPCSK9 Genechemistry.chemical_compound0302 clinical medicineRisk FactorsPhysiology (medical)Diabetes mellitusmedicineAnimalsHumansDyslipidemiasmedicine.diagnostic_testbusiness.industryCholesterolPCSK9Anticholesteremic AgentsPCSK9 InhibitorsAntibodies MonoclonalCholesterol LDLmedicine.diseaseFatty LiverHypocholesterolemia030104 developmental biologyTreatment OutcomechemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineLipid profilebusinessCognition DisordersBiomarkersLipoproteinCardiovascular research
researchProduct

No diagnostic utility of antibody patterns against Klebsiella pneumoniae capsular serotypes in patients with axial spondyloarthritis vs. patients wit…

2017

OBJECTIVES: To investigate whether antibody response patterns against Klebsiella pneumoniae capsular serotypes can discriminate patients with axial spondyloarthritis (axSpA) from patients with non-specific low back pain (LBP).METHOD: Immunoglobulin (Ig)G and IgA antibodies against K. pneumoniae capsular serotypes K2, K26, K36, and K50 were measured, and antibody seropositivity compared between groups and analysed for patient correlation in five different groups: (a) 96 patients fulfilling the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA; (b) 38 patients with either a positive magnetic resonance imaging (MRI) scan as defined by ASAS or a posi…

0301 basic medicineSerotypeMaleCross-sectional studyKlebsiella pneumoniaeDenmarkGastroenterology0302 clinical medicineImmunology and AllergyHLA-B27 Antigenbiologymedicine.diagnostic_testGeneral MedicineLow back painAntibodies BacterialMagnetic Resonance ImagingKlebsiella pneumoniaeC-Reactive ProteinFemaleAntibodymedicine.symptomAdultmedicine.medical_specialtyAdolescentImmunologyHuman leukocyte antigenSerogroup03 medical and health sciencesYoung AdultRheumatologyInternal medicineJournal ArticlemedicineHumansSpondylitis AnkylosingLow back painSacroiliitisBacterial Capsules030203 arthritis & rheumatologyAnkylosing spondylitisbusiness.industryta1182Magnetic resonance imagingaxial spondyloarthritismedicine.diseasebiology.organism_classificationantibody response patternsImmunoglobulin A030104 developmental biologyCase-Control StudiesImmunoglobulin GImmunologybiology.proteinSpondylarthropathiesbusinessLow Back Pain
researchProduct

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma

2016

CTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these effects, inducing T cell-mediated immune responses to various tumors including melanoma. Both anti-CTLA-4 and anti-PD-1 antibodies modify the interaction between tumor, antigen-presenting cells, and T lymphocytes. With respect to overall survival, clinical studies have shown a major benefit for the anti-CTLA-4 antibody ipilimumab as well as the two anti-PD-1 antibodies nivolumab and pembrolizumab. Following approval of ipilimumab in 2011, the latter two achieved market authorization in the summer of 2015. Immune responses thus…

0301 basic medicineSkin NeoplasmsDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classMedizinAntineoplastic AgentsIpilimumabDermatologyPembrolizumabMonoclonal antibody03 medical and health sciences0302 clinical medicineImmune systemmedicineHumansCTLA-4 AntigenMelanomabiologybusiness.industryMelanomaAntibodies Monoclonalmedicine.diseaseIpilimumabImmune checkpoint030104 developmental biology030220 oncology & carcinogenesisImmunologybiology.proteinNivolumabAntibodybusinessmedicine.drugJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence

2018

Although the progression of chronic lymphocytic leukemia (CLL) requires the cooperation of the microenvironment, the exact cellular and molecular mechanisms involved are still unclear. We investigated the interleukin (IL)-23 receptor (IL-23R)/IL-23 axis and found that circulating cells from early-stage CLL patients with shorter time-to-treatment, but not of those with a more benign course, expressed a defective form of the IL-23R complex lacking the IL-12Rβ1 chain. However, cells from both patient groups expressed the complete IL-23R complex in tissue infiltrates and could be induced to express the IL-12Rβ1 chain when cocultured with activated T cells or CD40L+ cells. CLL cells activated in…

0301 basic medicineStromal cellChronic lymphocytic leukemiaBiologyInterleukin-2303 medical and health sciencesParacrine signallingMice0302 clinical medicineRisk Factorshemic and lymphatic diseasesCell Line TumormedicineTumor MicroenvironmentAnimalsHumansAutocrine signallingCell ProliferationNeoplasm StagingTumor microenvironmentCD40Medicine (all)InterleukinGeneral MedicineReceptors Interleukinmedicine.diseaseAntibodies NeutralizingLeukemia Lymphocytic Chronic B-CellUp-RegulationLeukemia030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinLymph NodesStromal CellsSignal Transduction
researchProduct

Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer.

2019

Background:Many experimental studies have demonstrated the importance of COX-2 in the tumor angiogenesis. Inducible iNOS is responsible for a high and stable level of nitric oxide and is expressed in response to pro-inflammatory factors.Objective:The aim of this study was to evaluate the expression of COX-2 and iNOS at the protein level and to assess their potential prognostic significance in patients with endometrial cancer.Methods:The study group consisted of 45 women with endometrial cancer divided according to the degree of histological differentiation i.e. G1, 17; G2, 15; G3, 13. The control group consisted of 15 women without neoplastic changes. The expression of studied proteins was …

0301 basic medicineTumor angiogenesisAngiogenesisPharmaceutical ScienceNitric Oxide Synthase Type IINitric oxideAndrologyangiogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndometrial cancerMedicineHumansIn patientAgedmolecular markerbiologybusiness.industryEndometrial cancerProtein levelCOX-2Middle Agedneoplastic changesmedicine.diseasePrognosisReaction productEndometrial NeoplasmsiNOS030104 developmental biologychemistryPolyclonal antibodiesCyclooxygenase 2030220 oncology & carcinogenesisbiology.proteinFemaleNeoplasm GradingbusinessBiotechnologyCurrent pharmaceutical biotechnology
researchProduct

MicroRNAs miR-19, miR-340, miR-374 and miR-542 regulate MID1 protein expression.

2018

The MID1 ubiquitin ligase activates mTOR signaling and regulates mRNA translation. Misregulation of MID1 expression is associated with various diseases including midline malformation syndromes, cancer and neurodegenerative diseases. While this indicates that MID1 expression must be tightly regulated to prevent disease states specific mechanisms involved have not been identified. We examined miRNAs to determine mechanisms that regulate MID1 expression. MicroRNAs (miRNA) are small non-coding RNAs that recognize specific sequences in their target mRNAs. Upon binding, miRNAs typically downregulate expression of these targets. Here, we identified four miRNAs, miR-19, miR-340, miR-374 and miR-542…

0301 basic medicineUntranslated regionSmall interfering RNAPhysiologymetabolism [Microtubule Proteins]Alzheimer's DiseaseBiochemistryImmune PhysiologyMedicine and Health SciencesSmall interfering RNAsmetabolism [Transcription Factors]3' Untranslated RegionsImmune System ProteinsMultidisciplinarybiologyReverse Transcriptase Polymerase Chain ReactionMessenger RNAQRNuclear ProteinsNeurodegenerative DiseasesTranslation (biology)EnzymesUbiquitin ligaseCell biologyNucleic acidsNeurologyMicrotubule ProteinsMedicineOxidoreductasesLuciferasemetabolism [Nuclear Proteins]Research ArticleScienceUbiquitin-Protein LigasesImmunologyTransfectionResearch and Analysis MethodsReal-Time Polymerase Chain ReactionAntibodies03 medical and health sciencesMental Health and PsychiatrymicroRNAGeneticsHumansddc:610Non-coding RNAMolecular Biology TechniquesMolecular BiologyMessenger RNABiology and life sciencesThree prime untranslated regionHEK 293 cellsProteinsGene regulationphysiology [MicroRNAs]MicroRNAs030104 developmental biologyHEK293 CellsEnzymologybiology.proteinRNAProtein TranslationDementiaGene expressionTranscription FactorsMid1 protein human
researchProduct

Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study.

2019

Background: Autoimmune chronic spontaneous urticaria (aiCSU) is an important subtype of chronic spontaneous urticaria (CSU) in which functional IgG autoantibodies to IgE or its high-affinity receptor (FcεRI) induces mast cell degranulation and subsequent symptom development. However, it has not been tightly characterized. This study aimed to better define the clinical and immunological features and to explore potential biomarkers of aiCSU. Methods: This was a multinational, multicenter study of 182 CSU patients. The clinical features studied included: urticaria activity and impact (UAS7 and quality of life); autologous serum skin test (ASST); IgG anti-FcεRI and IgG anti-IgE; IgG-anti-thyrop…

0301 basic medicinechronic spontaneous urticariaMaleBasophilIgG autoantibodiesImmunoglobulin EAutoantigensHistamine Releasechemistry.chemical_compound0302 clinical medicineIron-Binding ProteinsImmunology and AllergyChronic UrticariaReceptorAutologous serum skin testbiologyDegranulationMiddle AgedChronic spontaneous urticariaAntibodies Anti-IdiotypicBasophilsmedicine.anatomical_structurePhenotypeAutologous serum skin testautologous serum skin testFemaleSymptom AssessmentHistamineAdultAdolescentImmunologyIodide PeroxidaseAutoimmune Diseases03 medical and health sciencesYoung Adultautoimmune CSUmedicineJournal ArticleHumansAgedAutoantibodiesbusiness.industryReceptors IgEAutoantibodyBasophil activation030104 developmental biology030228 respiratory systemchemistryImmunoglobulin GImmunologyBasophil activation assaysbiology.proteinAutoimmune CSUbusinessbasophil activation assaysBiomarkersAllergyREFERENCES
researchProduct

Uncoupling of dynamin polymerization and GTPase activity revealed by the conformation-specific nanobody dynab

2017

Dynamin is a large GTPase that forms a helical collar at the neck of endocytic pits, and catalyzes membrane fission (Schmid and Frolov, 2011; Ferguson and De Camilli, 2012). Dynamin fission reaction is strictly dependent on GTP hydrolysis, but how fission is mediated is still debated (Antonny et al., 2016): GTP energy could be spent in membrane constriction required for fission, or in disassembly of the dynamin polymer to trigger fission. To follow dynamin GTP hydrolysis at endocytic pits, we generated a conformation-specific nanobody called dynab, that binds preferentially to the GTP hydrolytic state of dynamin-1. Dynab allowed us to follow the GTPase activity of dynamin-1 in real-time. We…

0301 basic medicineendocrine systemGTP'MouseQH301-705.5FissionScienceEndocytic cycleGTPasemacromolecular substancesEndocytosisGeneral Biochemistry Genetics and Molecular BiologyGTP PhosphohydrolasesPolymerization03 medical and health sciences0302 clinical medicineMembrane fissiondynaminendocytosisHumansBiology (General)Dynamin IDynaminGeneral Immunology and MicrobiologyChemistryGeneral Neuroscienceconformational-specific nanobodyHydrolysisQRGeneral MedicineCell BiologyFibroblastsSingle-Domain Antibodiesenzyme030104 developmental biologyMembraneddc:540BiophysicsMedicineGuanosine Triphosphatebiological phenomena cell phenomena and immunitycell biology conformational-specific nanobody dynamin endocytosis enzyme human mouse030217 neurology & neurosurgeryResearch ArticleHumaneLife
researchProduct

Biomarkers for the Noninvasive Diagnosis of Endometriosis: State of the Art and Future Perspectives

2020

Background: Early and accurate diagnosis of endometriosis is crucial for the management of this benign, yet debilitating pathology. Despite the advances of modern medicine, there is no common ground regarding the pathophysiology of this disease as it continues to affect the quality of life of millions of women of reproductive age. The lack of specific symptoms often determines a belated diagnosis. The gold standard remains invasive, surgery followed by a histopathological exam. A biomarker or a panel of biomarkers is easy to measure, usually noninvasive, and could benefit the clinician in both diagnosing and monitoring the treatment response. Several studies have advanced the idea of biomar…

0301 basic medicineendometriosisProteomicsEndometriosisDiseaseReviewlcsh:ChemistryangiogenesisEndometrium0302 clinical medicinelcsh:QH301-705.5SpectroscopyOligonucleotide Array Sequence Analysis030219 obstetrics & reproductive medicineNeovascularization PathologicGeneral MedicineGenomicsComputer Science ApplicationsBiomarker (medicine)biomarkerFemalemedicine.medical_specialtyTreatment responseModern medicineCatalysisInorganic Chemistry03 medical and health sciencesmedicineHumansMetabolomicsurinary biomarkersPhysical and Theoretical ChemistryIntensive care medicineMolecular BiologyNoninvasive biomarkersAutoantibodiesInflammationbusiness.industryOrganic ChemistryGold standard (test)medicine.diseaseUrinary biomarkerscytokinesMicroRNAsOxidative Stress030104 developmental biologylcsh:Biology (General)lcsh:QD1-999businessPeptidesBiomarkersInternational Journal of Molecular Sciences
researchProduct